Login to Your Account

Word on the Street

Monday, December 19, 2011

"This is clinical development so there are going to be some setbacks."

Gil Van Bokkelen, CEO of Athersys Inc. and chairman of the Alliance for Regenerative Medicine

"You can see a slight change in subject one's pulse here. But I can tell you, his pulse was substantially lower than my own pulse when this vector was going in."

Amit Nathwani, investigator on a trial testing Factor IX gene therapy for hemophilia B, describing monitoring patients for adverse reaction during infusions

"If programs stumble, jobs are at stake."

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription